Procaspase 3 activation by combination therapy
AssigneesThe Board of Trustees of the University of Illinois, Vanquish Oncology, Inc.
InventorsPaul J. HERGENROTHER, Rachel C. BOTHAM, Timothy M. FAN, Mark J. GILBERT, Michael K. HANDLEY, Howard S. ROTH, Theodore M. TARASOW
Life of this patent
Estimating the term…
Abstract
The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.
Claims15
A method of treating cancer in a subject in need thereof comprising administering to a subject in need of therapy for cancer, concurrently or sequentially, a therapeutically effective amount of the compound PAC-1
- and an effective amount of a second active agent, wherein the second active agent is a topoisomerase inhibitor, a DNA intercalating agent, a mitotic inhibitor, a proteasome inhibitor, a protein kinase inhibitor, or a competitive agonist of the estrogen receptor;
- wherein the cancer is thereby treated.
Dependencies are inferred from the claim text.